Healthcare of Ontario Pension Plan Trust Fund Sells 2,051 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Healthcare of Ontario Pension Plan Trust Fund lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,949 shares of the biopharmaceutical company’s stock after selling 2,051 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Regeneron Pharmaceuticals were worth $10,457,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Prio Wealth Limited Partnership bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $210,000. Sanctuary Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $47,611,000. Kestra Investment Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $437,000. Souders Financial Advisors bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $801,000. Finally, Clearbridge Investments LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $1,506,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:REGN opened at $1,012.82 on Friday. The business’s 50 day simple moving average is $1,125.65 and its 200 day simple moving average is $1,036.98. The company has a market capitalization of $111.60 billion, a P/E ratio of 29.92, a P/E/G ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,033 shares of company stock valued at $9,399,345. 7.48% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada increased their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a research report on Friday. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,119.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.